Close Menu

NEW YORK – Cepheid said today that the US Food and Drug Administration has cleared its Xpert BCR-ABL Ultra test for monitoring disease burden in patients with chronic myeloid leukemia.

The in vitro diagnostic test can deliver accurate molecular results from whole blood samples in less than three hours, the company said in a statement. Measuring BCR-ABL gene transcript levels can indicate how well treatment for CML patients is working and predict relapses.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers have developed a robotic lab assistant, the Verge reports.

CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.

The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.

In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.